Article

Serum and Muscle $^1$H NMR-Based Metabolomics Profiles Reveal Metabolic Changes Influenced by a Maternal Leucine-Rich Diet in Tumor-Bearing Adult Offspring Rats

Natália Angelo da Silva Miyaguti $^1$, Danijela Stanisic $^2$, Sarah Christine Pereira de Oliveira $^3$, Gabriela Sales dos Santos $^1$, Beatriz Schincariol Manhe $^1$, Ljubica Tasic $^2$ and Maria Cristina Cintra Gomes-Marcondes $^1$*

$^1$ Laboratory of Nutrition and Cancer, Department of Structural and Functional Biology, Biology Institute, University of Campinas (UNICAMP), Rua Monteiro Lobato, 255, Campinas, SP 13083862, Brazil; namiyaguti@gmail.com (N.A.d.S.M.); sarah.pe9@gmail.com (S.C.P.d.O.); gabisalessantos@gmail.com (G.S.d.S.); beatrizschincariol16@gmail.com (B.S.M.)

$^2$ Chemical Biology Laboratory, Organic Chemistry Department, Institute of Chemistry, University of Campinas (UNICAMP), Rua Josué de Castro, s/n, Campinas, SP 13083970, Brazil; danijela@unicamp.br (D.S.); ljubica@unicamp.br (L.T.)

* Correspondence: cintgoma@unicamp.br; Tel.: +55-19-3521-6194

Received: 25 May 2020; Accepted: 10 July 2020; Published: 16 July 2020

Abstract: A maternal leucine-rich diet showed a positive effect on the gastrocnemius muscle of adult tumor-bearing offspring. To improve the understanding of the metabolic alterations of cancer cachexia and correlate this to preventive treatment, we evaluated the $^1$H NMR metabolic profiles from serum and gastrocnemius muscle samples of adult Wistar rats. These profiles were initially analyzed, and chemometrics tools were applied to investigate the following groups: C, control group; W, tumor-bearing group; L, the group without tumors and with a maternal leucine-rich diet; WL, the tumor-bearing group with a maternal leucine-rich diet. Tumor growth that led to a high protein breakdown in the W group was correlated to serum metabolites such as tyrosine, phenylalanine, histidine, glutamine, and tryptophan amino acids and uracil. Also, decreased muscle lactate, inversely to serum content, was found in the W group. Conversely, in the WL group, increased lactate in muscle and serum profiles was found, which could be correlated to the maternal diet effect. The muscle lipidomics and NAD$^+$, NADP$^+$, lysine, 4-aminohippurate, and glutamine metabolites pointed to modified energy metabolism and lower muscle mass loss in the WL group. In conclusion, this exploratory metabolomics analyses provided novel insights related to the Walker-256 tumor-bearing offspring metabolism modified by a maternal leucine-rich diet and the next steps in its investigation.

Keywords: cancer; cachexia; leucine; maternal nutrition; metabolomics; muscle wasting; serum

1. Introduction

Cancer cachexia syndrome is characterized by chronic systemic inflammation and progressive muscle wasting associated or not with fat mass loss. This multifactorial syndrome leads to an advanced functional impairment, which decreases the quality of life and the responses to treatment, being responsible for at least 22% of cancer-related deaths [1,2]. Therefore, strategies to prevent this condition are required. In this way, our previous study showed a maternal diet supplementation as a preventive approach against muscle wasting in an experimental model of cancer cachexia [3]. Based on leucine ability to cross the placental barrier and to modify the milk composition leading
to epigenetics marks on the offspring [4–6], our study demonstrated that a leucine-rich diet when maternally administered diminished the muscle mass loss in adult offspring tumor-bearing rats. This approach reduced the cachexia negative protein balance, which ameliorated the gastrocnemius muscle protein synthesis and decreased protein degradation, by activating the mechanistic target of rapamycin (mTOR) pathway and maintaining muscle cathepsin H and calpain activities [3].

Cancer cachexia syndrome leads to an intense metabolic alteration in the host, mainly on protein metabolism [7], and several studies have pointed that a leucine supplementation in cancer cachexia acts as a direct cell signal capable of activating the mTOR pathway, which improves the protein synthesis and minimizes the proteolytic pathways [8–10]. In our study, we focused on the maternal supplemented nutritional scheme with leucine as a candidate to modify the foetal epigenome and gene expression, impacting the offspring metabolism, thus interfering with disease susceptibility [11,12]. Leucine administration in premating rat dams has been explored to show its relation to improving the litter birth weight, as well as the improvement of the dams’ immune function and antioxidative capability [13]. In addition, concerning a possible leucine influence on insulin and glucose homeostasis, some studies reported that leucine supplementation during lactation in Wistar rats could improve the dams’ body composition, without compromising the offspring growth, and other studies referred to the predisposition to the obesity in adult offspring [14,15]. In this way, our study focused on the understanding of the metabolic responses provided by a maternal leucine-rich diet which minimized the muscle mass loss in tumor-bearing adult offspring.

The metabolomics allow studying the profiles of low molecular weight metabolite involved in the metabolism of an organism under certain physiological conditions, such as diseases and drug treatments [13,16]. Recently, some metabolomics studies identify the extensive changes in the levels of metabolites during cancer cachexia and can be used as a novel approach in maternal programming research [17–19]. Therefore, this study aimed to examine the maternal leucine-rich diet effects in serum and gastrocnemius muscle $^1$H NMR metabolic profiles of adult offspring tumor-bearing rats, to increase knowledge about the metabolic changes provided by this preventive approach. This metabolomics analyses provided novel insights related to the modified Walker-256 tumor-bearing offspring metabolism showing the effects of the tumor growth and the maternal leucine-rich diet in serum and gastrocnemius muscle metabolism, especially related to the protein breakdown and energy metabolism.

2. Materials and Methods

2.1. Animals and Diets

The experiment was approved by the Ethics Committee on Animal Experimentation of the Institute of Biology at the University of Campinas (protocol number: #4224-1) and is in accordance to the current ethical standards of the United Kingdom Coordinating Committee on Cancer Research [20].

Adults Wistar rats, 90 days old, were obtained from the Multidisciplinary Centre for Biological Research at the University of Campinas and were housed in individual cages at the experimental room located in the Laboratory of Nutrition and Cancer. The environmental conditions were controlled: 12 h light and dark cycle; humidity 50–60% and temperature 22 ± 2 °C. The animals were monitored daily and given free access to food and water.

The diets were prepared following the AIN-93, American Institute of Nutrition [21]. The control diet (C) contained 18% protein, of which 1.6% L-leucine, and the leucine-rich diet (L) had the same quantity of protein (18%) with the addition of 3% L-leucine (4.6% L-leucine in total). The amount of L-leucine was based on our previous experimental study [22].

2.2. Experimental Procedure

Females rats were mated, following the harem method [23]. After pregnancy detection, the female rats were separated from the males and distributed into two groups according to the diets administrated:
dams fed a control diet (n = 3), and dams fed a leucine-rich diet (n = 3). After birth, the offspring were reduced to 8 pups per litter. Throughout 21 days of gestation and 21 days of lactation, the dams were subjected to the indicated diets.

After weaning, all the male offspring received the Control diet. When they were 120 days old, the animals were randomly distributed into 4 groups according to the tumoral inoculation and maternal diet scheme, outlining the following groups:

- **C**, control group, offspring fed the Control diet throughout the intrauterine, lactation, and adulthood period, without tumors;
- **W**, tumor-bearing group, with a maternal Control diet throughout the intrauterine and lactation periods, with the offspring fed the control diet until the adulthood period, and tumor-bearing;
- **L**, the group without tumors and with a maternal leucine-rich diet influence throughout the intrauterine and lactation period, and with the offspring fed the Control diet until adulthood, without tumors;
- **WL**, the tumor-bearing group with a maternal leucine-rich diet influence throughout the intrauterine and lactation period, and with the offspring fed the Control diet until adulthood, and tumor-bearing.

The tumor-bearing groups (W and WL) received a subcutaneous tumor implant of approximately \(3 \times 10^6\) viable Walker-256 tumor cells, as previously described [24,25]. All the animals were euthanized by decapitation after 21 days of the tumor growth. After the euthanasia, blood samples were centrifuged at 12,000 \(\times g\) for 15 min, and the serum was collected and stored at \(-20^\circ C\). The left gastrocnemius muscles were resected and immediately frozen in liquid nitrogen and stored at \(-80^\circ C\).

Summing up, as reported in our previous work [3], independently of the nutritional scheme, the dams presented the same initial and final food intake, as well as the weight gain after gestation and lactation. Also, the litters were the same size, and the offspring weight evolution was not affected by the maternal diet.

### 2.3. Sample Preparation and \(^1\)H NMR Data Acquisition

Serum samples (0.5 mL) were filtered in a 3 kDa membrane, following the manufacturer instructions (Microcon YM-3 column, Amicon Ultra; Sigma-Aldrich, Saint Louis, MO, USA). The filtered serum obtained (0.2 mL) was diluted in an aqueous solution (0.6 mL) containing 10% (v/v) deuterium oxide (D\(_2\)O, 99.9%; Cambridge Isotope Laboratories Inc., Tewksbury, MA, USA), phosphate buffer (0.1 M, pH 7.4) and 0.5 mM 3-(trimethylsilyl)-2,2',3,3'-tetradeutero-propionic acid (TSP-d4; Sigma-Aldrich, Saint Louis, MO, USA), then transferred to a 5 mm NMR tube (Norell Standard Series 5 mm; Sigma-Aldrich, Saint Louis, MO, USA) for immediate acquisition. The number of replicates was 5–6 per group.

Gastrocnemius muscle samples (7–8 samples per group) were processed following Le Belle and colleagues' protocol [26]. Briefly, frozen gastrocnemius muscle samples (100 mg) were added to cold methanol/chloroform solution (2:1 v/v, in a total of 2.5 mL) and sonicated (VCX 500, Vibra-Cell; Sonics & Material Inc., Newtown, CT, USA) for 3 min with 10 s pause interval between each minute. Cold chloroform/distilled water solution (1:1 v/v, in a total of 2.5 mL) was then added, and the samples were briefly vortexed and centrifuged at 3.1 \(\times 10^3\) \(\times g\) for 20 min at 4 \(^\circ C\). The two phases obtained were collected in distinct tubes and dried in a vacuum concentrator (Vacufuge Concentrator; Eppendorf, Hamburg, Germany). The polar phase was rehydrated in 0.6 mL of D\(_2\)O-containing phosphate-buffered saline (0.1 M, pH 7.4) and 0.5 mM of TSP-d4 and the non-polar phase was mixed in 0.6 mL of chloroform. The solutions obtained were added to a 5mm NMR tube for immediate acquisition.

The \(^1\)H NMR spectra acquisition was performed using a Varian Inova NMR spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA) equipped with a triple resonance probe and operating at a \(^1\)H resonance frequency of 500 MHz and constant temperature of 298 K. A total of 256 free induction decays (FID) were collected with 32 K data points over a spectral width of 16 ppm. A 1.5 s relaxation delay was incorporated between scans, during which a continual water pre-saturation radio frequency (RF) field was applied.
2.4. Spectral Data Processing and Multivariable Statistical Analysis

The spectral data obtained were manually phased corrected and referenced to the methyl doublet signal of lactate (1.33 ppm) using MestReNova v.8.1.2 software (Mestrelab Research, Santiago de Compostela, Spain). Residual water signals (4.7–5.0 ppm) and peak-free regions were removed from further analysis. The remaining spectra (serum: 0.4–9.0 ppm; polar phase of muscle samples 0.8–9 ppm; and non-polar phase of muscle samples 0.3–10 ppm) were binned into bucketed data with widths of 0.005 ppm.

To extract the main differences between the groups, an initial spectral analysis was performed. The average of the NMR spectra of each group was calculated, and then subtracted as followed: the average of the spectra of the group W minus the average of the spectra of the group C to obtain the tumor effects; the average of the L spectra minus average the C spectra to obtain the maternal leucine-rich diet effect; the average of the WL spectra minus the average of the L spectra and minus the average of the W spectra to obtain the maternal diet effect on cancer development. Chemometrics and statistical analyses were performed using the MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/). Data normalization was carried out to consider sample concentrations variations using the probabilistic quotient normalization (PQN) method [27]. The data were first analyzed by principal component analysis (PCA) to extract and display the systematic variation in the data and to acquire an overview by presenting trends, groupings, and potential outliers [28]. Besides, to characterize intergroup differentiation, partial least squares-discriminant analysis (PLS-DA) was carried out. The cross-validation (LOOCV) method with accuracy performance measurement evaluated the performance of PLS-DA. The R2 and Q2 were calculated to fit and predict the capability of the model, respectively. The significance of variables was shown using the variable importance in the projection (VIP) values. The corresponding metabolites found in the VIP projection were identified by consulting the Chenomx Software database, The Human Metabolome Database (http://hmdb.ca) and Lipid Maps Database (http://www.lipidmaps.com).

To analyze the differences among groups, the relative metabolite abundance was quantified from the comparison of the internal standard (TSP-d4) concentration in the Profiler Chenomx module and then subjected to statistical analysis with a two-way ANOVA and the Bonferroni posthoc test (Graph Pad Prism software, version 5.0, San Diego, CA, USA) [29]. The results are expressed as the mean and standard error of the mean (SEM) and were considered significant when \( p < 0.05 \).

3. Results

3.1. Initial Spectral Analysis Showed Differences Related to the Walker-256 Tumour Growth and Maternal Leucine-Rich Diet in Serum Samples

A serum representative spectrum is presented in Figure S1, and the Table S1 corresponds to the metabolites assignment and respective chemical shifts. The differences found in serum during the initial spectral analysis showed higher peak intensity of lactate (1.33 ppm), tyrosine (6.92 and 7.19 ppm), histidine (7.09 and 7.34 ppm), phenylalanine (7.32 ppm, 7.53 ppm and 7.72 ppm), and tryptophan (7.19 ppm, 7.27 ppm, 7.31 ppm, 7.51 ppm) in the tumor-bearing group (W) in comparison to the control group (C) (Figure S2). The maternal leucine supplementation influenced the non-tumor-bearing group (L), where we observed enhancements in lactate, sugar (3.2–3.9 ppm), and in the aromatic amino acids, such as for tyrosine, histidine, and phenylalanine, when the L group was compared to the control group (C) (Figure S3). In relation to the tumor effect associated with maternal leucine-rich diet influence, the WL group showed had higher intensities of lactate, alanine (1.47 ppm) and tyrosine when compared to L group (Figure S4). Also, about the differences found between tumor-bearing groups (W and WL), lactate, tyrosine, histidine, phenylalanine and sugar showed higher intensities in the maternally leucine supplemented group (WL) (Figure S5).
3.2. Serum Chemometrics Analysis Reveals Metabolic Separation between the Groups and the Metabolites Responsible for this Differentiation

Initially, PCA analysis was applied to investigate all matrices obtained from $^1$H NMR serum spectra. The PCA score plot showed no separation, neither outliers among the groups. In this way, the PLS-DA was applied, and the model showed a differentiation among the groups as represented in the serum 3D PLS-DA score plot (Figure 1a; Accuracy = 0.174; $R^2$ = 0.967; $Q^2$ = 0.194, at the Component 2 (PC2) and Figure S6). The low Accuracy and the $Q^2$ values are due to the small number of samples, by high number of variables, around 1662 spectral bins, as expected for these analyses. For experimental studies, it is common to use a small size of samples per group, which is a limitation for some types of statistical analysis as presented here. The PC2 is 1.4% higher than Component 1 (PC1) in the Plot Score of the PLS-DA model. It is a small difference, because of the significant differences between the C, L, W groups and the WL group in PC2 (Figure 1a). It is statistically correct to obtain a higher value for PC1 than for PC2, but if the WL differs much in second component from the rest of the groups, thus the explained variances by PCs 1 and 2 may be different. The information for individual biomarkers responsible for this group separation was extracted from the VIP score loadings graph Figure S7) and the identified metabolites are presented in Table 1. The additional unsupervised analyses, Heatmap (Figure S8) for VIP's metabolites were performed, and showed the expected differences between the groups for each metabolite identified, in accordance with the performed obtained PLS-DA model, once more, showing a separation between the tumor and non-tumor-bearing groups. Some points also showed the potential of the leucine-rich diet in modulating the WL and L responses.
were lower in the L group when compared to the C group (Figure S11). Regarding the maternal growth and maternal leucine-rich diet (Figures S15–S18). The W group had higher peaks in 1.29 to 1.41 and 3.2 ppm in the acyl group region (Figure S12). In both tumor-bearing groups, the major di (3.76 ppm) were smaller, and the creatine intensity (3.05 and 3.95 ppm) was higher than the control low-density lipids, peaks of CH of WL versus the L group. There were lower peaks in WL group of saturated CH of triacylglycerol than the control group. However, the major di peaks in 1.24 to 1.25 ppm, and the acyl group of low-density lipids (from 5.24 to 5.33 ppm) for all experimental groups low-density lipids (from 0.80 to 0.85 ppm), the acyl group region of triacylglycerol (from 1.24 to 1.25 ppm), and the lactate and creatine region decreased in both tumor-bearing groups when compared to their controls (W < C, p = 0.0066; WL < L, p = 0.0331, respectively; Figure 1e,f), but the maternal leucine supplemented group (WL) showed no differences in these metabolites content.

3.3. Initial Spectral Analysis in Gastrocnemius Muscle Showed Differences Related to the Walker-256 Tumour Growth and Maternal Leucine-Rich Diet

A representative spectrum of muscle polar extract is presented in Figure S9, and the Table S1 corresponds to the metabolites assignment and respective chemical shifts. In the polar extract of the gastrocnemius muscle samples, the initial spectral analysis showed differences related to the tumor growth. In the W group, we observed that the peak intensity of the lactate (1.33 ppm) and anserine (3.76 ppm) were smaller, and the creatine intensity (3.05 and 3.95 ppm) was higher than the control group (Figure S10). About the maternal leucine rich-diet influence, the regions of lactate and creatine were lower in the L group when compared to the C group (Figure S11). Regarding the maternal leucine-rich diet influence over tumor growth, the WL group showed lower peak intensity in the regions of lactate and higher peaks intensity of creatine and anserine when compared to the L group (Figure S12). In both tumor-bearing groups, the major differences in muscle tissue were in the lactate and creatine, with higher intensities in the WL group. On the other hand, the anserine region decreased in the WL group in comparison to the W group (Figure S13).

A representative spectrum of muscle non-polar extract is presented in Figure S14, and the Table S2 corresponds to the metabolites assignment and respective chemical shifts. The initial spectral analysis of lipidomics of non-polar gastrocnemius muscle showed different peaks in the regions of very low-density lipids (from 0.80 to 0.85 ppm), the acyl group region of triacylglycerol (from 1.24 to 3.20 ppm), and the acyl group of low-density lipids (from 5.24 to 5.33 ppm) for all experimental groups (Figures S15–S18). The W group had higher peaks in 1.29 to 1.41 and 3.2 ppm in the acyl group region of triacylglycerol than the control group. However, the major difference found was in the comparison of WL versus the L group. There were lower peaks in WL group of saturated CH₃ group from the very low-density lipids, peaks of CH₂ near to acyl groups of triacylglycerol and acyl groups of low-density lipids.
lipids, when compared to the L group (Figure S17). In addition, the comparison of WL against W group showed higher peaks in 1.24 to 1.29 ppm in acyl group region of triacylglycerol needing to be more explored in relation to the maternal leucine-rich diet effect on tumor growth.

**Table 1.** Serum and muscle metabolites obtained from VIP (variable importance in the projection) score analysis of all different experimental groups with or without tumor implant, subjected or not to a maternal nutritional supplementation.

| VIP Score | Metabolites                  | Chemical Shifts (ppm) |
|-----------|------------------------------|-----------------------|
| Serum     | 4-aminohippurate             | 7.63 and 7.66         |
|           | AMP                          | 8.25                  |
|           | Cytidine                     | 6.01, 6.03 and 6.04   |
|           | Glutamine                    | 2.14                  |
|           | Lysine                       | 1.73 and 1.77         |
|           | Uracil                       | 7.52                  |
| Gastrocnemius Polar Extract | 2-deoxyuridine               | 6.24 and 6.26         |
|           | Adenosine                    | 8.26                  |
|           | Adenosine monophosphate      | 8.62                  |
|           | Anserine                     | 7.03                  |
|           | Histidine and Histamine      | 7.90                  |
|           | Isoleucine                   | 1.08                  |
|           | NAD+ and NADP+               | 6.03                  |
|           | Nicotinurate                 | 8.95 and 8.97         |
|           | O-acetylcarnitine            | 5.64                  |
| Gastrocnemius Non-Polar Extract | Glycerophospholipids       | 2.66 and 3.56         |
|           | Phosphatidylcholine          | 4.46                  |
|           | Polyunsaturated fatty acids  | 2.94 and 4.97         |
|           | Sphingomyelin                | 3.19                  |
|           | Triacylglycerols             | 2.57                  |
|           | Unsaturated octadecanoic acid|                      |

Legend: Metabolites obtained by the VIP score analysis and identified using the HMDB database, for serum and muscle samples, and LIPIDMAPS—Lipidomics Gateway for non-polar metabolites. More than one metabolite can be a candidate for some chemical shifts. Legend: C, Control group; W, Tumor-bearing group; L, Group without tumors and with a maternal leucine-rich diet; WL, Tumor-bearing group with a maternal leucine-rich diet. For more details, see Material and Method section.

### 3.4. Gastrocnemius Muscle Chemometrics Analysis Reveals the Metabolites Responsible for the Metabolic Segregation between the Tumour-Bearing Groups

The gastrocnemius muscle polar PCA score plot showed no significant differences between the groups, neither outliers among the groups and the 3D PLS-DA model showed a separation between the tumor-bearing groups and their respective controls. Also, an important difference was the separation between the tumor-bearing groups (W and WL) (Figure 2a; Accuracy = 0.166; R² = 0.960; Q² = 0.1, at the Component 3 (PC3) and Figure S19). The low values of Accuracy and Q² are due to the small number of samples and 1702 variables, spectral bins, used in chemometrics analysis. The extracted information
for each individual biomarker identified used from the VIP loading score graph (Figure S20) and the quantified metabolites are presented in Table 1. Additional unsupervised clustering analysis, as Heatmap (Figure S21) for VIP metabolites, was performed and showed results in same expected differences between the classes for each biomarker, which were in accordance with the performance obtained in the PLS-DA model, especially pointing to the differences provided by the maternal diet.

The metabolites quantified significantly different were 2-deoxyuridine, NAD$^+$ or NADP$^+$ and nicotinurate (Figure 2). Both tumor-bearing groups had higher metabolites concentrations for 2-deoxyuridine and nicotinurate when compared with their respectively controls groups (2-deoxyuridine: $W > C$, $p = 0.0132$; $WL > L$, $p = 0.0195$; nicotinurate: $W > C$, $p = 0.0282$; $WL > L$, $p = 0.0144$; Figure 2b,c). The NAD$^+$ and NADP$^+$ concentrations decreased in the W group when compared to control ($W < C$, $p = 0.0410$; Figure 2d), but the maternal leucine supplemented group WL had no change when compared to W and L groups.

The gastrocnemius muscle non-polar PCA score plot showed no separation, and no outliers among the groups. The 3D PLS-DA model for the NMR data of the extracted lipids from muscle samples showed a separation between the W and C group and, mainly, between the WL and L group. Also, we observed that the WL group tended towards a separation among the groups (Figure 2e, Accuracy = 0.207; $R^2 = 0.844$ and $Q^2 = 0.003$, at the PC2 and Figure S22). The low Accuracy and $Q^2$ values are due to the small number of samples by 1151 variables, spectral bins. The VIP scores from PLS-DA model showed the peaks responsible for this differentiation, and the respective metabolites are listed in Table 1.

Figure 2. Cont.
We found a modified gastrocnemius muscle metabolism due to the tumor evolution under the maternal with the cachexia metabolic alterations. Thus, the augmented serum concentration of tyrosine, histidine, also, the reduced muscle lactate and anserine and augmented 2-deoxyuridine, nicotinurate and creatine the lower muscle lactate in the W group could be a result of an exhaustion and less uptake of glucose as presented in our previous study [3].

The dielucine-rich diet e

Figure 2. Results obtained from gastrocnemius muscle samples from all experimental groups: (a) gastrocnemius muscle polar extract PLS-DA plot score; gastrocnemius muscle polar extract identified metabolites, as normalized concentrations (µM); (b) 2-deoxyuridine; (c) nicotinurate; (d) NAD⁺ and NADP⁺; (e) muscle non-polar extract PLS-DA plot score. Legend: C, Control group (n = 7–8); W, Tumor-bearing group (n = 7); L, Group without tumors and with a maternal leucine-rich diet (n = 7–8); WL, Tumor-bearing group with a maternal leucine-rich diet (n = 8). For more details, see Material and Method section. *, p < 0.05 for statistical difference compared to C group; †, p < 0.05 for statistical difference compared to L group.

4. Discussion

In this work, we showed for the first time the metabolomics profiles of serum and muscle tissue amino acid of cancer cachexia under the influence of a maternal leucine-rich diet. We found a modified gastrocnemius muscle metabolism due to the tumor evolution under the maternal leucine-rich diet effects. Also, reflecting the offspring overall metabolism status and the derangement led by the muscle wasting, the serum metabolomics indicated different metabolic responses among the experimental groups. Thus, even in the short period of gestation and lactation, the maternal nutritional supplementation could modulate the adult offspring serum and gastrocnemius muscle metabolic responses.

Firstly, we evaluated the modified metabolites related to the tumor growth, specifically associated with the cachexia muscle alterations. Thus, the augmented serum concentration of tyrosine, histidine, phenylalanine, and tryptophan, as found here, is in line with other metabolomics studies with tumor-bearing animals, including Walker-256 tumor, which correlated the elevation of these metabolites to a higher protein breakdown [25,30,31]. In tumor-bearing animals, the enhanced serum lactate can be originated by the higher glycolytic process converting glucose into pyruvate, which is then converted into lactate or also in alanine by non-oxidative pathways, instead of being oxidized in the Krebs cycle, as postulated by the “Warburg effect” [32]. Excessive lactate production can exacerbate energy expenditure and is associated with impaired protein renewal, further damaging to the cachectic host, as seen in our previous study [3]. The serum lactate was inversely related to the muscle profile in the tumor-bearing group and associated to an increased muscle creatine concentration, likely corresponding to muscle wasting and a profound alteration on metabolic pathways related to muscle protein breakdown. Also, the reduced muscle lactate and anserine and augmented 2-deoxyuridine, nicotinurate and creatine found in the tumor-bearing group are consistent with metabolomics studies on cancer cachexia [33,34]. The lower muscle lactate in the W group could be a result of an exhaustion and less uptake of glucose as major muscle source energy [35]. Also, a depletion of the anserine antioxidant peptide, as seen in this study, could be related to increased oxidative stress [36], in line with all altered processes in cachexia presented in our previous study [3].

The different metabolic profiles found here were correlated to an increased protein breakdown led by cachexia, counterbalanced by the improvement in food intake and increased muscle protein turnover in tumor-bearing adult offspring rats from a maternal leucine-rich diet, as showed by the

![Figure 2](image-url)
activation of the mTOR pathway and the maintenance of muscle cathepsin H and calpain activities, described in our previous study [3]. In this way, notably, the WL and the L group also presented an elevation in serum lactate, tyrosine, histidine, and phenylalanine showing the maternal diet capacity of altering these metabolites concentrations, independent of the tumor presence. Also, it is interesting to emphasize that even with higher levels of muscle lactate (WL > W), in the tumor-bearing maternally leucine supplemented group this parameter was lower in the gastrocnemius muscle associated with maintained contents of NAD$^+$ and NADP$^+$, when compared to L group. Thus, this maintenance needs to be further explored since recent studies linked the reduced NAD$^+$ levels to mitochondrial dysfunction and derangements in muscle mass and strength, leading to muscle wasting [37]. Therefore, the improved protein turnover found in the WL group, showed in our previous study, could possibly be associated with these metabolites alteration, likely indicating a differential use of lactate as a muscular energy source, requiring further studies in this way.

A study by Peters and colleagues showed the role of L-leucine therapeutic administration in preserving muscle mass loss in cancer cachectic mice. The authors observed that C26 tumor-bearing group exhibited an increased protein breakdown with high levels of specific serum amino acids, including lysine, while, under treatment, the leucine supplemented group had an attenuation of muscle mass spoliation, reflecting decreased total plasma amino acids. [38]. In line with this study, but now focusing on a preventive leucine administration, here we presented that the tumor-bearing group showed an increase in lysine serum concentration, consistently with the increased protein breakdown, associated with low protein synthesis [3]. On the other hand, we observed that the maternal leucine supplementation could modulate the lysine concentration in the tumor-bearing group, being probably related to the lower muscle mass loss, as previously shown [3]. Also, we found an increase in serum uracil and cytidine metabolites in both tumor-bearing groups possibly being correlated with the rapid growth and cell proliferation of the cancer cells [39,40], since no differences were found between the tumor-bearing groups by similar tumor weight, as showed in our previous study [3]. The low levels found of serum glutamine could be associated with its hypermetabolism commonly found in cancer situations. This amino acid is preferably used as a fuel for rapidly dividing cells, providing a source of nitrogen for other synthesis reactions and a carbon skeleton to the tricarboxylic acid cycle; besides, this amino acid is a precursor of glutathione, as well as for the synthesis of nucleotides and lipids, usually impaired in cachexia [30,41]. Also, this serum decrease could represent the reduced branched-chain amino acids (BCAA) availability as a nitrogen source commonly found in cancer cachexia [42]. In this way, the maternal leucine-rich diet also contributed to the maintenance of the concentration of 4-amino-hippurate, a phenylalanine metabolite. As phenylalanine is related to protein synthesis and even to energy metabolism, this alteration can be likely related to the maintenance of the muscle mass found in the WL group and being different from the intense spoliation found in the tumor-bearing group [3].

To our knowledge, there are few works correlating a lipidomics profile and cancer cachexia in literature. In one of them, a serum metabolomics study of O’Connel and colleagues hypothesized the elevation of glycerol, free fatty acids, very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) serum levels in cachectic animals as a possible consequence of mobilization of fatty acids and amino acids from the adipose and muscle tissues by the lipid mobilization factor (LMF) produced during the tumor growth [43]. Meanwhile, here we presented that the gastrocnemius muscle lipidomics could be consistent with the profound cancer cachexia metabolic disruption in lipid metabolism [43–45]. In the PLS-DA model, we found a metabolic separation related to the tumor growth and to the maternal diet, which in the WL group had the highest separation. Therefore, this fact showed the relationship between modified metabolism and the improved responses under the maternal leucine diet influence. In our study, we showed that the main gastrocnemius muscle lipids modification was in the content of triacylglycerols, lipoproteins (LDL and VLDL), and also lipids related to the cell membrane as glycerophospholipids, phosphatidylcholine, polyunsaturated fatty acids, and sphingomyelin. This lipid metabolomic profile in muscle, as shown for the first time here,
may lead us to further studies on the cell membrane lipid disorder, which could affect cellular activities and responses to tumor-induced damage. Therefore, the metabolic deregulation that links cancer progression and the high demand for energy production could be related to these changes in muscle lipid composition, which needs further studies to correlate to the consequences on muscle metabolism, as verified here. In addition, our study in cachectic muscle preliminarily indicates lipid candidates to be explored concerning the development of cachexia and the understanding of the capacity of the maternal leucine-rich diet to alter some characteristics of muscle lipid metabolism.

Studies using omics as a way of investigation always have some limitations [17]. Thus, some points should be addressed here, as the PCA and PLS-DA methods are normally suitable for greater number of samples, providing the variable contribution for the separation among the groups. Besides, the univariate tests such as ANOVA were also performed showing no significant differences in some metabolites peaks, nor metabolites described as significant for groups separation, for this reason, we choose the VIP score from the PLS-DA model and the initial spectral analysis to represent the groups separation. In this way, we opted to lose some statistical power with a small sample size that is ethically accepted by the Animals Ethics Committee, aiming for study reproducibility, with modest cohorts to address our questions, but making this work an exploratory metabolomics analysis. These points were taken into account within a careful evaluation, which provided the opportunity to raise new points for further studies in our research area.

5. Conclusions

In conclusion, this exploratory metabolomics analyses raised novel insights related to the impaired metabolism in the Walker-256 tumor-bearing animals and the modulatory effect of the maternal leucine-rich diet in modifying the adult offspring serum and muscle metabolism, as summarized up in Table 2. Due to the complexity of the cancer cachexia metabolic derangement and the complex epigenetics modifications provided by the maternal diet, the integration with other “omics” techniques should be considered in further studies which may help a better understanding of the epigenetic effect provided by the maternal leucine supplementation in the adult offspring tumor-bearing animals.

Table 2. Summarized results and future perspectives of the differences found in serum and gastrocnemius muscle polar metabolites in all experimental groups, showing the maternal leucine supplementation influence.

| Comparisons | Serum Metabolites | Muscle Polar Metabolites | Implications and Future Perspectives |
|--------------|-------------------|--------------------------|-------------------------------------|
| W vs. C      | ↑Lactate, Tyrosine, Histidine, Phenylalanine, Tryptophan, Uric, 4-aminohippurate, Lysine | ↑Creatine, 2-deoxyuridine, Nicotinurate | Amino acids related to protein breakdown. |
|              |                   |                          | Inverse correlation of serum and muscle lactate related to the Warburg effect and muscle wasting. |
|              |                   |                          | Disrupted energy consumption needs to be further explored concerning muscle mitochondrial dysfunction. |
|              | ↓Glutamine, Lactate, Lactate, Anserine |                      |                                       |
| L vs. C      | ↑Lactate, Sugar regions, Tyrosine, Histidine, Phenylalanine | Lactate, Anserine, NAD” and NADP” | Amino acids changes and lactate inversely correlated in serum and muscle as a maternal diet effect. |
|              |                   |                          | Future exploration of this impact in non-tumor-bearing animals. |
Table 2. Cont.

| Comparisons | Serum Metabolites | Muscle Polar Metabolites | Implications and Future Perspectives |
|--------------|-------------------|--------------------------|--------------------------------------|
| WL vs. I     | Lactate           | Creatine                 | - Augmented serum lactate and inverse correlation in muscle demands investigations. |
|              | Alanine           | Anserine                 | - Augmented amino acids and uracil associated to glutamine diminishment as possible effects of tumor development. |
|              | Tyrosine          | 2-deoxyuridine           | - Candidates to be explored in relation to decreased muscle spoliation and energy metabolism: lysine; 4-aminohippurate and NAD+ and NADP+. |
|              | Cytidine          | Nicotinurate             |                                      |
|              | Uracil            |                          |                                      |
| WL vs. W     | Glutamine         | Lactate                  | - Amino acids related to protein breakdown. |
|              | 4-aminobutyric acid | Lysine                  | - Maternal diet effect: serum and muscle lactate increase demands investigation. |
|              |                   | NAD+ and NADP+           |                                      |
| WL           | Sugar regions     | Lactate                  |                                      |
|              | Tyrosine          | Creatine                 |                                      |
|              | Histidine         |                          |                                      |
|              | Phenylalanine     |                          |                                      |

Legend: C, Control group; W, Tumor-bearing group; L, Group without tumors and with a maternal leucine-rich diet; WL, Tumor-bearing group with a maternal leucine-rich diet. For more details, see Material and Method section.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/7/2106/s1.
Figure S1. Representative $^1$H NMR serum spectra of a sample of the control group identifying 34 metabolites, in amplified spectral regions from 5.1–7.1 ppm, 6.7–8.6 ppm, 2.7–4.8 ppm and 0.8–2.9 ppm from the bottom to the top, and numbered peaks of metabolites, which were assigned as shown in Table S1; Figure S2. Comparison of $^1$H NMR data of serum samples between W and C groups to evaluate the tumor effects. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the C group; Figure S3. Comparison of $^1$H NMR data of serum samples between WL and L groups to evaluate the maternal diet effect. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the C group; Figure S4. Comparison of $^1$H NMR data of serum samples between WL and L groups to evaluate the maternal diet effect. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the L group; Figure S5. Comparison of $^1$H NMR data of serum samples between WL and L groups to evaluate the maternal diet effect. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the L group; Figure S6. Accuracy, R2 and Q2 for PLS-DA model for four classes (C; L; W: WL) from serum $^1$H NMR spectra; Figure S7. Important variables (VIPs) of peaks chemical assignments extracted from PLS-DA, loadings plots for the experimental groups (C; L; W: WL) from serum $^1$H NMR spectra; Figure S8. Heatmap plot for PLS-DA model for the experimental groups (C; L; W: WL) from serum $^1$H NMR spectra; Figure S9. Representative $^1$H NMR spectra of 37 polar metabolites found in gastrocnemius extract form a sample of the control group, in amplified spectral regions from 5.0–9.9 ppm, 0.8–5.4 ppm and 0.7–5.4 ppm from the bottom to the top, and numbered peaks of metabolites, which were assigned as shown in Table S1; Figure S10. Comparison of $^1$H NMR data of polar metabolites of gastrocnemius muscle samples between W and C groups to evaluate the tumor effects. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the C group; Figure S11. Comparison of $^1$H NMR data of polar metabolites of gastrocnemius muscle samples between W and C groups to evaluate the tumor effects. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the C group; Figure S12. Comparison of $^1$H NMR data of polar metabolites of gastrocnemius muscle samples between W and C groups to evaluate the tumor effects. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the C group; Figure S13. Comparison of $^1$H NMR data of polar metabolites of gastrocnemius muscle samples between W and C groups to evaluate the maternal diet effect on cancer development. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the W group; Figure S14. Representative $^1$H NMR gastrocnemius non-polar muscle spectra of a control group sample with 19 peaks found and assignment from 0.8 to 6.0 ppm; Figure S15. Comparison of $^1$H NMR data of non-polar metabolites of gastrocnemius muscle samples between W and C groups to evaluate the tumor effects. The graphic represents the average of the NMR spectra of the W group minus the average of the NMR spectra of the C group; Figure S16. Comparison of $^1$H NMR data of non-polar metabolites of gastrocnemius muscle samples between W and C groups - to evaluate the maternal diet effect. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the L group; Figure S17. Comparison of $^1$H NMR data of non-polar metabolites of gastrocnemius muscle samples between WL and L groups - to evaluate the maternal diet effect. The graphic represents the average of the NMR spectra of the WL group minus the average of the NMR spectra of the L group; Figure S18. Comparison of $^1$H NMR data of non-polar metabolites of gastrocnemius muscle samples between WL and W groups to evaluate the
maternal diet effect on cancer development. The graphic represents the average of the NMR spectra of the WL group minus average of NMR spectra of the W group; Figure S19. Accuracy, R2 and Q2 for PLS-DA model for the experimental groups (C; L; W: WL) from polar gastrocnemius extract of 1H NMR spectra; Figure S20. Important variables (VIPs), peaks chemical assignments extracted from PLS-DA loadings plots for the experimental groups (C; L; W: WL) from nonpolar gastrocnemius extract of 1H NMR spectra; Figure S21. Heatmap plot for PLS-DA VIPs for the experimental groups (C; L; W: WL) generated for polar gastrocnemius extract of 1H NMR spectra; Figure S22. Accuracy, R2 and Q2 for PLS-DA model for the experimental groups (C; L; W: WL) from nonpolar gastrocnemius extract of 1H NMR spectra; Table S1. Serum and muscle polar metabolites, and their chemical shifts, spectral peak multiplicities and coupling constants found in samples analyzed for all experimental groups, shown as 1–37 peaks in Figures S1 and S9; Table S2. Total lipids presented in gastrocnemius muscle non-polar extract and their chemical shifts, corresponding to the Figure S14.

**Author Contributions:** Conceptualization, N.A.d.S.M.; data curation, N.A.d.S.M., G.S.d.S. and B.S.M.; formal analysis, N.A.d.S.M., D.S., S.C.P.d.O. and M.C.C.G.-M.; funding acquisition, M.C.C.G.-M.; investigation, N.A.d.S.M., D.S., S.C.P.d.O., G.S.d.S., B.S.M., L.T. and M.C.C.G.-M.; methodology, N.A.d.S.M., D.S. and L.T.; project administration, M.C.C.G.-M.; resources, M.C.C.G.-M.; supervision, N.A.d.S.M. and M.C.C.G.-M.; validation, N.A.d.S.M. and M.C.C.G.-M.; writing—original draft, N.A.d.S.M., D.S., S.C.P.d.O., L.T. and M.C.C.G.-M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Fundação de Amparo à Pesquisa de São Paulo (FAPESP), grant number #2015/13334-7, #2017/10809-2, #2017/02739-4, 2019/13957-7; Conselho Nacional de Desenvolvimento Tecnológico (CNPq), grant number #302524/2016-9 and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), grant number 001.

**Acknowledgments:** The authors acknowledge Maurício Luís S Força for his help with NMR methodology and data acquisition; Rafael Rossi Valentim and Carla de Moraes Salgado for their help with NMR data acquisition and Rogério Willians Santos for assistance with animal care. L-Leucine was donated by Ajinomoto Brazil (São Paulo, Brazil).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Argilés, J.M.; Stemmler, B.; Lópíz-Soriano, F.J.; Busquets, S. Inter-tissue communication in cancer cachexia. *Nat. Rev. Endocrinol.* 2018. [CrossRef]
2. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and classification of cancer cachexia: An international consensus. *Lancet Oncol.* 2011, 12, 489–495. [CrossRef]
3. da Silva Miyaguti, N.A.; de Oliveira, S.C.P.; Gomes-Marcondes, M.C.C. Maternal Leucine-Rich Diet Minimises Muscle Mass Loss in Tumour-bearing Adult Rat Offspring by Improving the Balance of Muscle Protein Synthesis and Degradation. *Biomolecules* 2019, 9, 229. [CrossRef] [PubMed]
4. Regnault, T.R.H.; de Vrijer, B.; Battaglia, F.C. Transport and Metabolism of Amino Acids in Placenta. *Endocrine* 2002, 19, 23–41. [CrossRef]
5. Viana, L.R.; Gomes-Marcondes, M.C.C. Leucine-Rich Diet Improves the Serum Amino Acid Profile and Body Composition of Fetuses from Tumor-Bearing Pregnant Mice. *Biol. Reprod.* 2013, 88, 1–8. [CrossRef] [PubMed]
6. Melnik, B.C. Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation. *Int. J. Mol. Sci.* 2015, 16, 17048–17087. [CrossRef]
7. Porporato, P.E. Understanding cachexia as a cancer metabolism syndrome. *Oncogenesis* 2016, 5, e200. [CrossRef]
8. Saxton, R.A.; Sabatiní, D.M. mTOR Signaling in Growth, Metabolism, and Disease. *Cell* 2017, 168, 960–976. [CrossRef]
9. Costelli, P.; Reffo, P.; Penna, F.; Autelli, R.; Bonelli, G.; Baccino, F.M. Ca(2+)-dependent proteolysis in muscle wasting. *Int. J. Biochem.* 2005, 37, 2134–2146. [CrossRef]
10. Fearon, K.C.H.; Glass, D.J.; Guttridge, D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways. *Cell Metab.* 2012, 16, 153–166. [CrossRef]
11. Mathias, P.C.F.; Elmhiri, G.; De Oliveira, J.C.; Delayre-Orthez, C.; Barella, L.F.; Tófolo, L.P.; Fabricio, G.S.; Chango, A.; Abdennebi-Najar, L. Maternal diet, bioactive molecules, and exercising as reprogramming tools of metabolic programming. *Eur. J. Nutr.* 2014, 53, 711–722. [CrossRef] [PubMed]
12. Chango, A.; Pogribny, I.P. Considering maternal dietary modulators for epigenetic regulation and programming of the fetal epigenome. *Nutrients* 2015, 7, 2748–2770. [CrossRef] [PubMed]

13. Kosmides, A.K.; Kamisoglu, K.; Calvano, S.E.; Corbett, S.A.; Androulakis, I.P. Metabolomic Fingerprinting: Challenges and Opportunities. *Crit Rev. Biomed. Eng.* 2013, 41, 205–221. [CrossRef]

14. López, N.; Sánchez, J.; Picó, C.; Palou, A.; Serra, F. Dietary l-leucine supplementation of lactating rats results in a tendency to increase lean/fat ratio associated to lower orexigenic neuropeptide expression in hypothalamus. *Peptides* 2010, 31, 1361–1367. [CrossRef] [PubMed]

15. López, N.; Sánchez, J.; Palou, A.; Serra, F. Gender-associated impact of early leucine supplementation on adult predisposition to obesity in rats. *Nutrients* 2018, 10, 76. [CrossRef]

16. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. *Nat. Rev. Drug Discov.* 2016, 15, 473–481. [CrossRef] [PubMed]

17. Gallagher, I.J.; Jacobi, C.; Tardif, N.; Rooyackers, O.; Fearon, K. Omics/systems biology and cancer cachexia. *Semin. Cell Dev. Biol.* 2016, 54, 92–103. [CrossRef] [PubMed]

18. Twelkmeyer, B.; Tardif, N.; Rooyackers, O. Omics and cachexia. *Curr. Opin. Clin. Nutr. Metab. Care* 2017, 20, 181–185. [CrossRef]

19. Reeves, P.G.; Nielsen, F.H.; Fahey, G.C., Jr. AIN-93 Purified Diets for Laboratory Rodents: Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. *J. Nutr.* 1993, 123, 1939–1951. [CrossRef]

20. da Silva Miyaguti, N.A.; de Oliveira, S.C.P.; Gomes-Marcondes, M.C.C. Maternal nutritional supplementation with fish oil and/or leucine improves hepatic function and antioxidant defenses, and minimizes cachexia indexes in Walker-256 tumor-bearing rats offspring. *Nutr. Res.* 2018, 51, 29–39. [CrossRef] [PubMed]

21. Baker, D.E.J. Reproduction and breeding. In *The Laboratory Rat*; Baker, H.J., Lindsey, J.R., Weisbroth, S.H., Eds.; Academic Press: New York, NY, USA, 1979; Volume 1, pp. 153–168.

22. Gomes-Marcondes, M.C.C.; Curi, R.; Cury, L. Consequences of Walker 256 tumour growth for the placental/foetal development in rats. *J. Cancer Res. Ther.* 1998, 5, 277–283.

23. Viana, L.R.; Canevarolo, R.; Luiz, S.C.; Corbett, S.A.; Androulakis, I.P. Metabolomic Fingerprinting of Systems Biology and Cancer Cachexia. *Curr. Opin. Clin. Nutr. Metab. Care* 2013, 811–814. [CrossRef]

24. Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabolomics. *Anal. Chem.* 2006, 78, 4281–4290. [CrossRef]

25. Le Belle, J.E.; Harris, N.G.; Williams, S.R.; Bhakoo, K.K. A comparison of cell and tissue extraction techniques using high-resolution 1H-NMR spectroscopy. *NMR Biomed.* 2002, 15, 37–44. [CrossRef] [PubMed]

26. Dieterle, F.; Ross, A.; Schlotterbeck, G.; Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabolomics. *Anal. Chem.* 2006, 78, 4281–4290. [CrossRef]

27. Stoffel, M.; Bassols, A. Skeletal muscle metabolism and blood biochemistry analysis reveal metabolic changes associated with dietary amino acid supplementation in dairy calves. *Sci. Rep.* 2018, 8, 1–12. [CrossRef] [PubMed]
34. Pérez-Rambla, C.; Puchades-Carrasco, L.; García-Flores, M.; Rubio-Briones, J.; López-Guerrero, J.A.; Pineda-Lucena, A. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. *Metabolomics* 2017, 13, 1–12. [CrossRef]

35. Cui, P.; Shao, W.; Huang, C.; Wu, C.; Jiang, B.; Lin, D. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia. *Skelet. Muscle* 2019, 9, 3. [CrossRef]

36. Der-Torossian, H.; Wysong, A.; Shadfar, S.; Willis, M.S.; McDunn, J.; Couch, M.E. Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia. *J. Cachexia. Sarcopenia Muscle* 2013, 4, 145–155. [CrossRef]

37. Migliavacca, E.; Tay, S.K.H.; Patel, H.P.; Sonntag, T.; Civiletto, G.; McFarlane, C.; Forrester, T.; Barton, S.J.; Leow, M.K.; Antoun, E.; et al. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. *Nat. Commun.* 2019, 10. [CrossRef]

38. Peters, S.J.; van Helvoort, A.; Kegler, D.; Argilès, J.M.; Luiking, Y.C.; Laviano, A.; van Bergenhenegouwen, J.; Deutz, N.E.P.; Haagsman, H.P.; Gorselink, M.; et al. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice. *Oncol. Rep.* 2011, 26, 247–254. [CrossRef] [PubMed]

39. Frickenschimidt, A.; Frohlich, H.; Bullinger, D.; Zell, A.; Laufer, S.; Gleiter, C.H.; Liebich, H.; Kammaer, B. Metabonomics in cancer diagnosis: Mass spectrometry-based profiling of urinary nucleosides from breast cancer patients. *Biomarkers* 2008, 13, 435–449. [CrossRef] [PubMed]

40. Lo, W.; Jeng, L.; Lai, C.; Tsai, F.; Lin, C.; Chen, W.T. Urinary cytidine as an adjunct biomarker to improve the diagnostic ratio for gastric cancer in Taiwanese patients. *Clin. Chim. Acta* 2014, 428, 57–62. [CrossRef] [PubMed]

41. Wu, G. Amino acids: Metabolism, functions, and nutrition. *Amino Acids* 2009, 37, 1–17. [CrossRef]

42. Pin, F.; Barreto, R.; Couch, M.E.; Bonetto, A.; O’Connell, T.M. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. *J. Cachexia. Sarcopenia Muscle* 2019, 10, 140–154. [CrossRef] [PubMed]

43. O’Connell, T.M.; Ardeshpour, F.; Asher, S.A.; Winnike, J.H.; Yin, X.; George, J.; Guttridge, D.C.; He, W.; Wysong, A.; Willis, M.S.; et al. Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. *Metabolomics* 2008, 4, 216–225. [CrossRef]

44. Der-Torossian, H.; Asher, S.A.; Winnike, J.H.; Wysong, A.; Yin, X.; Willis, M.S.; O’Connell, T.M.; Couch, M.E. Cancer cachexia’s metabolic signature in a murine model confirms a distinct entity. *Metabolomics* 2013, 9, 730–739. [CrossRef]

45. Cala, M.P.; Agulló-Ortuño, M.T.; Prieto-García, E.; González-Riano, C.; Parrilla-Rubio, L.; Barbas, C.; Díaz-García, C.V.; García, A.; Pernaut, C.; Adeva, J.; et al. Multiprotform platform plasma fingerprinting in cancer cachexia: A pilot observational and translational study. *J. Cachexia Sarcopenia Muscle* 2018, 9, 348–357. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).